Market Context — Why This Technology, Why Now

The biopharmaceutical and biotech sectors are increasingly prioritizing product consistency and regulatory compliance, driving demand for highly controlled cell culture environments. Simultaneously, the push for sustainable food sources is fueling rapid growth in the cultured meat industry, which requires scalable and reliable cell proliferation technologies. This technology aligns perfectly with these trends, offering a solution to enhance reproducibility, reduce development risks, and accelerate market entry for next-generation biological products.

Key Competitive Advantages
01

Precisely controls cell genetic expression by minimizing unknown growth factor interference, ensuring consistent target cell properties.

02

Significantly reduces variability in culture results for R&D and manufacturing by eliminating external factors, enabling reliable data acquisition.

03

Establishes a long-term barrier to competition with patent protection until 2040, supporting stable business expansion.

Market Opportunity
Regenerative Medicine and Cell Therapy
$100B–$150B globally (AI est.)
Advancements in iPSC research and the transition to practical application phases necessitate high-purity, highly reproducible cell culture substrates.
Leading regenerative medicine developers Cell therapy manufacturers Biotech firms specializing in iPSCs
Cultured Meat and Alternative Proteins
$5B–$15B globally (AI est.)
Efficient and stable cell culture technology is critical for reducing environmental impact and ensuring food security.
Cultured meat startups and scale-ups Food technology companies Large-scale protein producers
Drug Discovery Screening and Research
$30B–$40B globally (AI est.)
Improved precision in disease model cells is expected to enhance the efficiency and success rate of new drug development.
Pharmaceutical R&D divisions Contract research organizations (CROs) Academic research institutions
IP Defensibility — Why Competitors Can't Replicate This
What This Patent Covers

This patent successfully secured broad protection after strategically navigating the pre-appeal examination system and meeting stringent criteria. It covers the hydrogel's composition, manufacturing method, gel kit, and cell culture product manufacturing methods across 29 claims. The patent's robustness is evidenced by its allowance after overcoming nine prior art references and a refusal, indicating a strong, difficult-to-invalidate intellectual property.

Competitive White Space

While this patent robustly protects the hydrogel and its core applications, white space exists in optimizing bioreactor designs specifically for this hydrogel, developing advanced real-time monitoring systems for cell behavior within the gel, or engineering novel cell lines for enhanced compatibility and performance.

Economic Impact
~$100K/year estimated R&D cost reduction per facility (est.)
estimated ROI · USD · AI analysis
ROI Calculation Logic

Assuming a reduction in cell culture failure rates from a conventional 10% to 2%, a laboratory performing 1,000 cultures annually could save 80 culture runs. At an estimated cost of ~$1,350/run (media, reagents, labor), this translates to an annual R&D cost reduction of ~$108,000 (AI est.). This also contributes to faster development cycles through improved experimental reproducibility.

Speed to Market
4× faster than in-house development
This technology's fundamental mechanisms have been established through R&D by a national research institution and are protected by patent. This significantly reduces the development period for licensees compared to starting from scratch. The radiation crosslinking and polymer material expertise are highly compatible with existing technological infrastructures, allowing for efficient validation and optimization post-adoption. This could shorten time-to-market by approximately 3 years.
Competitive Positioning

X: Cell Culture Purity and Stability
Y: R&D Efficiency and Reproducibility

Business Models & Applications
🤝 Technology Licensing
Granting rights for the hydrogel manufacturing technology and cell culture methods to licensees, enabling product development, manufacturing, and sales to support broad market expansion.
🧪 Joint Research and Development
Combining the licensee's specific cell line or application expertise with this technology to jointly develop new products or services in regenerative medicine or cultured meat.
🏭 Contract Manufacturing & Material Supply
Manufacturing high-purity hydrogels using this technology and supplying them as materials to regenerative medicine research institutions or cultured meat producers, securing a stable revenue stream.
Adjacent Application Opportunities
🔬 Drug Discovery & R&D
High-Precision Disease Models
Leveraging this technology's stable genetic expression control, high-precision cell models can be constructed to replicate specific disease mechanisms. This could significantly enhance the efficiency and accuracy of new drug candidate screening, potentially shortening development timelines by up to 20%.
🥩 Cultured Meat Industry
Standardized Cultured Meat Quality
Stabilizing cell proliferation and genetic expression during the culture process could standardize the cellular composition and texture of cultured meat. This would improve product quality consistency, potentially accelerating market acceptance and mass production by ~30%.
💉 Regenerative Medicine
Enhanced Safety & Efficacy for Therapeutic Cells
Stabilizing the quality of therapeutic cells and eliminating unknown growth factor interference improves the predictability of cell behavior post-transplantation. This could enhance the safety and efficacy of regenerative medicine products, accelerating clinical applications and reducing failure rates by up to 8%.
Integration Roadmap — Estimated 24-Month Deployment
Technology Evaluation & Prototype Development
Duration: 6 months
Evaluate the hydrogel properties and compatibility with the licensee's cell culture processes, then develop a small-scale prototype.
Process Optimization & Validation
Duration: 9 months
Conduct performance validation under actual cell culture conditions using the developed prototype and optimize the process for scale-up.
Mass Production & Market Launch
Duration: 9 months
Establish a mass production system based on the optimized process and introduce the product to target markets such as regenerative medicine and cultured meat.
Technical Feasibility
This technology's hydrogel features a radiation-crosslinked hydrophilic polymer structure, offering high compatibility with existing cell culture equipment and operational procedures. Designed as a gel kit, it eliminates the need for complex material preparation, allowing licensees to easily apply it to existing culture plates and bioreactors. Radiation crosslinking is a common polymer processing technique, enabling adoption with minimal specialized equipment investment.
Success Scenario
Upon adopting this technology, the regenerative medicine sector could see up to a 20% improvement in differentiation efficiency from iPSCs to target cells. This could enable a stable supply of high-purity therapeutic cells, expanding treatment opportunities for patients and potentially reducing medical costs. In the cultured meat sector, cell proliferation rates could accelerate by 1.5 times, potentially shortening manufacturing periods by approximately 30%.
Patent Record
APPLICATION NO.
特願2020-527697
REGISTRATION NO.
7414224
FILING DATE
2019/06/28
GRANT DATE
2024/01/05
EXPIRATION DATE
2039/06/28
PATENT HOLDER
国立研究開発法人量子科学技術研究開発機構
Examination History
2021年01月14日
手続補正書（自発・内容）
2021年02月15日
手続補正書（自発・内容）
2021年02月15日
出願審査請求書
2021年04月09日
手続補正書（自発・内容）
2022年03月22日
拒絶理由通知書
2022年07月21日
手続補正書（自発・内容）
2022年07月21日
意見書
2022年11月22日
拒絶理由通知書
2023年03月22日
手続補正書（自発・内容）
2023年03月22日
意見書
2023年06月27日
拒絶査定
2023年09月26日
手続補正書（自発・内容）
2023年10月03日
審査前置移管
2023年10月10日
審査前置移管通知
2023年11月28日
特許査定
2023年12月01日
審査前置登録